Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
Hardman Johnston Large Cap Equity Hardman Johnston Global Advisors LLC | “Illumina, with almost 70% market share in gene sequencing, has weathered a storm of life science funding cuts and competitive entries. While the coast is not completely clear, they remain well positioned to benefit from any acceleration in both clinical and research spending in the life sciences. BSD Analysis: Illumina remains the backbone of genomic sequencing, even as regulatory missteps and execution errors have punished the stock. The core sequencing franchise is still unrivaled in scale, accuracy, and installed base, which creates massive switching costs. Near-term growth has been weighed down by funding slowdowns in biotech and academic research. However, demand for genomics is structural, driven by oncology, diagnostics, and population-scale sequencing programs. Cost cuts and refocus on the core business are restoring margin credibility. The failed Grail acquisition damaged trust, but it did not erode Illumina's technological moat. Investors treat Illumina like a broken growth story rather than an infrastructure asset in biology. As funding cycles normalize, volumes tend to rebound sharply. This is a wounded monopoly, not a displaced one.” | BULL | Q4 2025 Dec 31, 2025 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
